Author

Andrew A. Bolinger

Observed names: Andrew A Bolinger, Andrew A. Bolinger

Institution: University of Louisiana at Monroe

Observed institutions: The University of Texas Medical Branch at Galveston, University of Louisiana at Monroe

ORCID: 0000-0002-1645-3827

Observed ORCID: 0000-0002-1645-3827

OpenAlex ID: A5071999090

Novel approaches to targeted protein degradation technologies in drug discovery

2023 · Yu Xue, Andrew A. Bolinger, et al. · Expert Opinion on Drug Discovery · 52

PDF

Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases

2021 · Yi Li, Jianping Chen, et al. · Inflammatory Bowel Diseases · 43

Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)

2023 · Zonghui Ma, Andrew A. Bolinger, et al. · Journal of Medicinal Chemistry · 34

PDF

Highlights on Fluorine-containing Drugs Approved by U.S. FDA in 2023

2024 · Saghir Ali, Andrew A. Bolinger, et al. · Current Topics in Medicinal Chemistry · 30

PDF

RIPTACs: A groundbreaking approach to drug discovery

2023 · Zonghui Ma, Andrew A. Bolinger, et al. · Drug Discovery Today · 30

An updated patent review of BRD4 degraders

2024 · Zonghui Ma, Cun Zhang, et al. · Expert Opinion on Therapeutic Patents · 29

PDF

Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target

2023 · Andrew A. Bolinger, Andrew Frazier, et al. · ACS Chemical Neuroscience · 26

PDF

Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics

2023 · Zonghui Ma, Andrew A. Bolinger, et al. · Expert Opinion on Therapeutic Targets · 26

PDF

Therapeutic potential of salicylamide derivatives for combating viral infections

2023 · Jimin Xu, Yu Xue, et al. · Medicinal Research Reviews · 21

PDF

Design, synthesis, and pharmacological evaluations of pyrrolo[1,2-a]quinoxaline-based derivatives as potent and selective sirt6 activators

2022 · Jimin Xu, Shuizhen Shi, et al. · European Journal of Medicinal Chemistry · 18

Discovery of Novel Oleamide Analogues as Brain-Penetrant Positive Allosteric Serotonin 5-HT2C Receptor and Dual 5-HT2C/5-HT2A Receptor Modulators

2023 · Jianping Chen, Erik J. Garcia, et al. · Journal of Medicinal Chemistry · 15

PDF

Lessons learnt from broad-spectrum coronavirus antiviral drug discovery

2024 · Andrew A. Bolinger, Jun Li, et al. · Expert Opinion on Drug Discovery · 10

PDF

BRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease

2024 · Zonghui Ma, Andrew A. Bolinger, et al. · Advances in pharmacology · 5

The Effect of Serotonin 5‐HT 2C Receptor Modulation on Binge Drinking and Alcohol‐Seeking in Female Mice

2025 · Roberta G. Anversa, Linh Tran, et al. · Addiction Biology · 1

Serendipitous Discovery of Novel 5-HT2AR Positive Allosteric Modulators (PAMs) Derived From 5-HT2CR PAM Scaffolds

2024 · Joshua C. Zamora, Christina R. Merritt, et al. · Journal of Pharmacology and Experimental Therapeutics · 1

The Serotonin 5-ht2areceptor as an Evolving Neurotherapeutic Target

2023 · Andrew A. Bolinger, Noelle C. Anastasio, et al. · Medicinal chemistry reviews · 1

Exploring New Vista for Alzheimer's Disease Drug Targets (Part II)

2023 · Andrew A. Bolinger, Jia Zhou · Current Topics in Medicinal Chemistry · 1

PDF

Artificial intelligence revolutionizing CNS drug discovery and development

2026 · Md E.K. Talukder, Mohammad Rashedul Islam, et al. · Drug Discovery Today

Works count: 18

Citation count: 343

H-index: 11

I10-index: 12